Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

British Journal of Cancer
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. british journal of cancer
  3. regular article
  4. article
Modulation of paclitaxel resistance by annexin IV in human cancer cell lines
Download PDF
Download PDF
  • Regular Article
  • Open access
  • Published: 06 June 2000

Modulation of paclitaxel resistance by annexin IV in human cancer cell lines

  • E Kyu-Ho Han1 na1,
  • S K Tahir1 na1,
  • S P Cherian1,
  • N Collins1 &
  • …
  • S-C Ng1 

British Journal of Cancer volume 83, pages 83–88 (2000)Cite this article

  • 1962 Accesses

  • 98 Citations

  • Metrics details

This article has been updated

Abstract

A recurring problem with cancer therapies is the development of drug resistance. While investigating the protein profile of cells resistant to a novel antimitotic compound (A204197), we discovered an increase in annexin IV expression. When we examined the annexin IV protein expression level in a paclitaxel-resistant cell line (H460/T800), we found that annexin IV was also overexpressed. Interestingly a closely related protein, annexin II, was not overexpressed in H460/T800 cells. Immunostaining with either annexin II or IV antibody revealed that annexin IV was primarily located in the nucleus of paclitaxel-resistant H460/T800 cells. Short-term treatment of H460 cells with 10 nM paclitaxel for up to 4 days resulted in induction of annexin IV, but not annexin II expression. In addition, there was an increase in annexin IV staining in the nucleus starting at day 1. Furthermore, cells pretreated with 10 nM paclitaxel for 4 days resulted in cells becoming ~fivefold more resistant to paclitaxel. Transfection of annexin IV cDNA into 293T cells revealed that there was a threefold increase in paclitaxel resistance. Thus our results indicate that annexin IV plays a role in paclitaxel resistance in this cell line and it is among one of the earliest proteins that is induced in cells in response to cytotoxic stress such as antimitotic drug treatment. © 2000 Cancer Research Campaign

Similar content being viewed by others

Antibody–drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells

Article Open access 01 April 2021

ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study

Article Open access 23 December 2022

Anti-cancer effects of human placenta-derived amniotic epithelial stem cells loaded with paclitaxel on cancer cells

Article Open access 28 October 2022

Article PDF

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  • Barwise JL and Walker JH (1996) Annexins II, IV, V and VI relocate in response to rises in intracellular calcium in human foreskin fibroblasts. J Cell Sci 109: 247–255

    CAS  PubMed  Google Scholar 

  • Benz J and Hofmann A (1997) Annexins: from structure to function. Biol Chem 78: 177–183

    Google Scholar 

  • Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J and Neckers L (1995) Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res 55: 4623–4626

    CAS  PubMed  Google Scholar 

  • Cabral F, Abraham I and Gottesman MM (1981) Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in α-tubulin. Proc Natl Acad Sci USA 78: 4388–4391

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cole SPC, Pinkoski MJ, Bhardwaj G and Deeley RG (1992) Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br J Cancer 65: 498–502

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dubois T, Oudinet JP, Mira JP and Russo-Marie F (1996) Annexins and protein kinase C. Biochim Biophys Acta 1313: 290–294

    Article  PubMed  Google Scholar 

  • Germann UA (1996) P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A: 927–944

    Article  CAS  PubMed  Google Scholar 

  • Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JTM, Fojo T and Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118–17125

    Article  CAS  PubMed  Google Scholar 

  • Gottesman MM and Pastan I (1988) The multidrug transporter, a double-edged sword. J Biol Chem 263: 12163–12166

    CAS  PubMed  Google Scholar 

  • Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385–427

    Article  CAS  PubMed  Google Scholar 

  • Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD and Horwitz SB (1995) Altered expression of Mβ2, the class II β-tubulin isotype, in a murine J744.2 cell line with a high level of taxol resistance. J Biol Chem 270: 31269–31277

    Article  CAS  PubMed  Google Scholar 

  • Han EK-H, Sgambato A, Jiang W, Zhang Y-U, Santella RM, Doki Y, Cacace A, Schieren I and Weinstein IB (1995) Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. Oncogene 10: 953–961

    CAS  PubMed  Google Scholar 

  • Han EK-H, Begemann M, Sgambato A, Soh J-W, Xing W-Q and Weinstein IB (1996) Increased expression of cyclin D1 in a murine mammary epithelial cell line inhibits growth and enhances apoptosis. Cell Growth Differ 7: 699–710

    CAS  PubMed  Google Scholar 

  • Han EK-H, Gehrke L, Tahir SK, Credo RB, Cherian SP, Sham H, Rosenberg SH and Ng SC (1999) Modulation of multidrug resistance by α-tubulin in taxol resistant human lung cancer cell line. Eur J Cancer,

  • Kavallaris M, Kuo DY-S, Burkhart CA, Regl DL, Norris MD, Haber M and Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 100: 1282–1293

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kavallaris M, Burkhart CA and Horwitz SB (1999) Antisense oligonuclotides to class III β-tubulin sensitize drug-resistant cells to taxol. Br J Cancer 80: 1020–1025

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT and Bates SE (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharm 46: 627–638

    CAS  Google Scholar 

  • Lehnert M (1996) Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 32A: 912–920

    Article  CAS  PubMed  Google Scholar 

  • Mohiti J, Caswell AM and Walker JH (1995) Calcium-induced relocation of annexins IV and V in the human osteosarcoma cell line MG-63. Mol Mem Biol 12: 321–329

    Article  CAS  Google Scholar 

  • Nygren P, Larsson R, Gruber A, Peterson C and Bergh J (1991) Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterized by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression. Br J Cancer 64: 1011–1018

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • O’Farrell PH (1975) High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250: 4007–4021

    PubMed  Google Scholar 

  • Ranganathan S, Dexter DW, Benetatos CA and Hudes GR (1988) Cloning and sequencing of human βIII-tubulin cDNA: induction of βIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. Biochim Biophy Acta 1395: 237–245

    Article  Google Scholar 

  • Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD and Hudes GR (1996) Increase of βIII- and βIV-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 56: 2584–2589

    CAS  PubMed  Google Scholar 

  • Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW and Hudes GR (1998) Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77: 562–566

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Raynal P, Kuijpers G, Rojas E and Pollard HB (1996) A rise in nuclear calcium translocate annexins IV and V to the nuclear envelope. FEBS Lett 392: 263–268

    Article  CAS  PubMed  Google Scholar 

  • Rowinsky EK and Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332: 1004–1014

    Article  CAS  PubMed  Google Scholar 

  • Rowinsky EK, Onetto N, Canetta RM and Arbuck SG (1992) Taxol: the first of the taxanes, an important new class of antitumor agents. Sem Oncol 19: 646–662

    CAS  Google Scholar 

  • Sjolin C, Stendahl O and Dahlgren C (1994) Calcium-induced translocation of annexins to subcellular organelles of human neutrophils. Biochem J 300: 325–330

    Article  PubMed  PubMed Central  Google Scholar 

  • Schibler MJ and Cabral F (1986) Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha-and beta-tubulin. J Cell Biol 102: 1522–1531

    Article  CAS  PubMed  Google Scholar 

  • Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Keney S and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107–1112

    Article  CAS  PubMed  Google Scholar 

  • Smith PD and Moss SE (1994) Structural evoluation of the annexin supergene family. Trends in Genetics 10: 241–246

    Article  CAS  PubMed  Google Scholar 

  • Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T and Wimalasena J (1998) Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 273: 4928–4936

    Article  CAS  PubMed  Google Scholar 

  • Wolfson M, Yang CPH and Horwitz SB (1997) Taxol induces tyrosine phosphorylation of Shc and its association with Grb2 in murine RAW 264.7 cells. Int J Cancer 70: 248–252

    Article  CAS  PubMed  Google Scholar 

  • Yang CPH, Galbiati F, Volonte D, Horwitz SB and Lisanti MP (1998) Upregulation of caveolin-1 and caveola organelles in taxol-resistant A549 cells. FEBS Lett 439: 368–372

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes
  1. E Kyu-Ho Han and S K Tahir: Authors contributed equally to this work

Authors and Affiliations

  1. Pharmaceutical Products Division, Department 4N6, Cancer Research, Building AP9, Abbott Laboratories, Abbott Park, 60064-3500, IL, USA

    E Kyu-Ho Han, S K Tahir, S P Cherian, N Collins & S-C Ng

Authors
  1. E Kyu-Ho Han
    View author publications

    Search author on:PubMed Google Scholar

  2. S K Tahir
    View author publications

    Search author on:PubMed Google Scholar

  3. S P Cherian
    View author publications

    Search author on:PubMed Google Scholar

  4. N Collins
    View author publications

    Search author on:PubMed Google Scholar

  5. S-C Ng
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and permissions

About this article

Cite this article

Han, EH., Tahir, S., Cherian, S. et al. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer 83, 83–88 (2000). https://doi.org/10.1054/bjoc.2000.1311

Download citation

  • Received: 15 November 1999

  • Revised: 25 January 2000

  • Accepted: 27 January 2000

  • Published: 06 June 2000

  • Issue date: 01 July 2000

  • DOI: https://doi.org/10.1054/bjoc.2000.1311

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • annexin
  • paclitaxel
  • drug resistance
  • antimitotic

This article is cited by

  • Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma

    • Chang-Yu Chen
    • Yung-Song Lin
    • Yin-Ju Chen

    Journal of Biomedical Science (2018)

  • Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer

    • Ruikai Du
    • Bingjie Liu
    • Suling Liu

    Cell Death & Disease (2018)

  • Toosendanin mediates cisplatin sensitization through targeting Annexin A4/ATP7A in non-small cell lung cancer cells

    • Mao Dong Zheng
    • Nai Dong Wang
    • Zhihua Zhang

    Journal of Natural Medicines (2018)

  • Prognostic significance of annexin A2 and annexin A4 expression in patients with cervical cancer

    • Chel Hun Choi
    • Joon-Yong Chung
    • Stephen M. Hewitt

    BMC Cancer (2016)

  • Annexin A4-nuclear factor-κB feedback circuit regulates cell malignant behavior and tumor growth in gallbladder cancer

    • Hou-Shan Yao
    • Chang Sun
    • Zhi-Qian Hu

    Scientific Reports (2016)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Follow us on Twitter
  • Sign up for alerts
  • RSS feed

About the journal

  • Journal Information
  • Open access publishing
  • About the Editors
  • Contact
  • Special Issues
  • For Advertisers
  • Subscribe

Publish with us

  • For Authors & Referees
  • Language editing services
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

British Journal of Cancer (Br J Cancer)

ISSN 1532-1827 (online)

ISSN 0007-0920 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited